Behrouz Kassai

Summary

Country: France

Publications

  1. pmc Treatment of high blood pressure and gain in event-free life expectancy
    Behrouz Kassai
    Department of Clinical Pharmacology, Claude Bernard University, Lyon, France
    Vasc Health Risk Manag 1:163-9. 2005
  2. ncbi Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?
    Behrouz Kassai
    EA 643 Clinical Pharmacology Unit, Claude Bernard University, Facultá RTH Laennec, Rue Guillaume Paradin BP 8071 69376, Lyon 08, France
    J Clin Epidemiol 56:977-82. 2003
  3. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
  4. doi SCORE should be preferred to Framingham to predict cardiovascular death in French population
    Ivanny Marchant
    IMTh Institute for Theoretical Medicine CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Service de Pharmacologie Clinique, Lyon, France
    Eur J Cardiovasc Prev Rehabil 16:609-15. 2009
  5. pmc The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
    Behrouz Kassai
    Department of Clinical Pharmacology EA 3736, University Hospital of Lyon, Rue Guillaume Paradin, BP 8071, Lyon cedex 08 69376, France
    J Clin Epidemiol 58:1042-51. 2005
  6. pmc A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
    Behrouz Kassai
    Clinical Pharmacology Unit, Rue Guillaume Paradin BP8071 69376, Lyon Cedex 08, France
    Thromb Haemost 91:655-66. 2004
  7. pmc Literature search parameters marginally improved the pooled estimate accuracy for ultrasound in detecting deep venous thrombosis
    Behrouz Kassai
    Clinical Investigation Centre INSERM, Department of Clinical Pharmacology EA 3736, Hôpitaux de Lyon, Universite Claude Bernard Lyon I, Lyon Cedex 08, France
    J Clin Epidemiol 59:710-4. 2006
  8. ncbi [New approaches in pharmacology: numerical modelling and simulation]
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Faculté RTH Laënnec et Hôpital Cardiologique, Lyon, France
    Therapie 60:1-15. 2005
  9. doi Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure
    Anne Charlotte Castellan
    Universite de Lyon, F 69000, Lyon, Universite Lyon 1, CNRS UMR5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe Modélisation et Evaluation des Thérapeutiques, 7 rue Guillaume Paradin, 69007 Lyon, France
    Clin Pharmacokinet 52:199-209. 2013
  10. ncbi Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data
    Behrouz Kassai
    INSERM, CIC201, EPICIM, Lyon, France
    Epilepsia 49:343-8. 2008

Detail Information

Publications13

  1. pmc Treatment of high blood pressure and gain in event-free life expectancy
    Behrouz Kassai
    Department of Clinical Pharmacology, Claude Bernard University, Lyon, France
    Vasc Health Risk Manag 1:163-9. 2005
    ..Consideration of absolute risk has been recommended for making decisions concerning preventive treatment in hypertension. We performed simulations to estimate the benefit of antihypertensive therapy over a life-time...
  2. ncbi Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?
    Behrouz Kassai
    EA 643 Clinical Pharmacology Unit, Claude Bernard University, Facultá RTH Laennec, Rue Guillaume Paradin BP 8071 69376, Lyon 08, France
    J Clin Epidemiol 56:977-82. 2003
    ..Considering the gain in event-free life expectancy, low-risk patients benefit more than high-risk patients do, at the expense of a longer treatment exposure. The interpretation of the AB changes depending on follow-up...
  3. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
    ..Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may increase mortality...
  4. doi SCORE should be preferred to Framingham to predict cardiovascular death in French population
    Ivanny Marchant
    IMTh Institute for Theoretical Medicine CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Service de Pharmacologie Clinique, Lyon, France
    Eur J Cardiovasc Prev Rehabil 16:609-15. 2009
    ..Numerous studies have examined the validity of available scores to predict the absolute cardiovascular risk...
  5. pmc The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
    Behrouz Kassai
    Department of Clinical Pharmacology EA 3736, University Hospital of Lyon, Rue Guillaume Paradin, BP 8071, Lyon cedex 08 69376, France
    J Clin Epidemiol 58:1042-51. 2005
    ..by the reference standard a valid surrogate? (2) How does the tests accuracy influence the estimate of the treatment benefit on surrogate? (3) Is it possible to correct the measured treatment effect given by results of inaccurate tests?..
  6. pmc A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
    Behrouz Kassai
    Clinical Pharmacology Unit, Rue Guillaume Paradin BP8071 69376, Lyon Cedex 08, France
    Thromb Haemost 91:655-66. 2004
    ..Our results suggest that, particularly for proximal veins, ultrasound is accurate for the diagnosis of DVT in asymptomatic postoperative orthopedic patients. More research is needed in other clinical settings...
  7. pmc Literature search parameters marginally improved the pooled estimate accuracy for ultrasound in detecting deep venous thrombosis
    Behrouz Kassai
    Clinical Investigation Centre INSERM, Department of Clinical Pharmacology EA 3736, Hôpitaux de Lyon, Universite Claude Bernard Lyon I, Lyon Cedex 08, France
    J Clin Epidemiol 59:710-4. 2006
    ..Our objectives were to compare search strategies with and without methodological terms in Medline, to find out how other databases complement Medline, and how these strategies affect the pooled estimates of the accuracy...
  8. ncbi [New approaches in pharmacology: numerical modelling and simulation]
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Faculté RTH Laënnec et Hôpital Cardiologique, Lyon, France
    Therapie 60:1-15. 2005
    ..Such approaches are considered in drug innovation and development. They require a multidisciplinary approach, and this will involve modification of the way research in pharmacology is conducted...
  9. doi Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure
    Anne Charlotte Castellan
    Universite de Lyon, F 69000, Lyon, Universite Lyon 1, CNRS UMR5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe Modélisation et Evaluation des Thérapeutiques, 7 rue Guillaume Paradin, 69007 Lyon, France
    Clin Pharmacokinet 52:199-209. 2013
    ..We then developed dosing recommendations based on genotypes and compared them to current Epar/Vidal dosing guidelines...
  10. ncbi Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data
    Behrouz Kassai
    INSERM, CIC201, EPICIM, Lyon, France
    Epilepsia 49:343-8. 2008
    ..The two RCTs identified, however, were performed with the same objectives and design and showed that seizure frequency is greatly reduced by stiripentol in children with SMEI after 2 months of treatment...
  11. doi [Public clinical trials: which kind of monitoring should be used?]
    Catherine Cornu
    Service de Pharmacologie Clinique, Lyon, France
    Therapie 68:135-41. 2013
    ..Our objective was to describe the most frequent quality failures, how they impact trial results, and identify the most efficient monitoring strategies using published articles and reports...
  12. pmc Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    BMJ 343:d4169. 2011
    ..To determine all cause mortality and deaths from cardiovascular events related to intensive glucose lowering treatment in people with type 2 diabetes...
  13. ncbi The assessment of deep vein thromboses for therapeutic trials
    Alain Leizorovicz
    Clinical Pharmacology Department, University Claude Bernard, Faculte Laennec, Rue Guillaume Paradin, Lyon, France
    Angiology 54:19-24. 2003
    ..Compression ultrasonography has already been adopted as the principal method for evaluating DVT in several ongoing large scale prevention trials with the approval of major drug agencies...